We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+6.31%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$852M
AUM Growth
+$151M
Cap. Flow
+$154M
Cap. Flow %
18.03%
Top 10 Hldgs %
46.73%
Holding
164
New
33
Increased
26
Reduced
31
Closed
28

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$28.9M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$14.6M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$9.62M
4
FOLD
Amicus Therapeutics
FOLD
+$9.34M
5
PRTA icon
Prothena Corp
PRTA
+$7.38M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$18.6M
2
BIIB icon
Biogen
BIIB
+$9.88M
3
ITRN icon
Ituran Location and Control
ITRN
+$8.27M
4
ORBK
Orbotech Ltd
ORBK
+$6.41M
5
ZGNX
Zogenix, Inc.
ZGNX
+$5.08M

Sector Composition

Rank Sector Weight
1 Healthcare 58.93%
2 Technology 3.62%
3 Communication Services 2.25%
4 Financials 1.01%
5 Consumer Discretionary 0.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HON icon
51
Honeywell
HON
$77B
$4.1M 0.48%
+29,612
New +$3.97M
KDMN
52
DELISTED
Kadmon Holdings, Inc.
KDMN
$3.98M 0.47%
1,100,000
– –
GBT
53
DELISTED
Global Blood Therapeutics, Inc.
GBT
$3.94M 0.46%
100,000
-27,000
-21% -$1.01M
CTSH icon
54
Cognizant
CTSH
$24.9B
$3.91M 0.46%
55,086
+24,220
+78% +$1.77M
CHTR icon
55
Charter Communications
CHTR
$17.3B
$3.91M 0.46%
11,629
-1,733
-13% -$589K
IMMU
56
DELISTED
Immunomedics Inc
IMMU
$3.72M 0.44%
230,000
-220,000
-49% -$2.6M
AVEO
57
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$3.63M 0.43%
130,000
-10,000
-7% -$310K
ANAB icon
58
AnaptysBio
ANAB
$1.58B
$3.52M 0.41%
35,000
-45,000
-56% -$3.31M
PBYI icon
59
Puma Biotechnology
PBYI
$404M
$3.46M 0.41%
+35,000
New +$3.92M
XFOR icon
60
X4 Pharmaceuticals
XFOR
$375M
$3.44M 0.4%
+1,496
New +$3.78M
VBIV
61
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$3.42M 0.4%
+26,667
New +$3.28M
CTMX icon
62
CytomX Therapeutics
CTMX
$675M
$3.38M 0.4%
160,000
-50,000
-24% -$1.04M
ABEO icon
63
Abeona Therapeutics
ABEO
$366M
$3.33M 0.39%
+8,400
New +$3.47M
ALNA
64
DELISTED
Allena Pharmaceuticals
ALNA
$3.27M 0.38%
+325,000
New +$4.01M
IMGN
65
DELISTED
Immunogen Inc
IMGN
$3.21M 0.38%
+500,000
New +$3.08M
MLNT
66
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$3.16M 0.37%
+40,000
New +$2.96M
CLSD
67
DELISTED
Clearside Biomedical
CLSD
$3.15M 0.37%
30,000
+10,000
+50% +$1.07M
PDSB icon
68
PDS Biotechnology
PDSB
$38.4M
$3.13M 0.37%
16,687
– –
BMRN icon
69
BioMarin Pharmaceuticals
BMRN
$11.6B
$3.12M 0.37%
35,000
-50,000
-59% -$4.35M
CMTA
70
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$3.09M 0.36%
163,000
– –
LRCX icon
71
Lam Research
LRCX
$367B
$3.05M 0.36%
+165,800
New +$3.26M
BOLD
72
DELISTED
Audentes Therapeutics, Inc
BOLD
$2.97M 0.35%
95,000
– –
SVRA icon
73
Savara
SVRA
$1.12B
$2.97M 0.35%
200,000
-326,315
-62% -$3.74M
TXMD icon
74
TherapeuticsMD
TXMD
$23.5M
$2.9M 0.34%
9,600
+2,000
+26% +$557K
NBIX icon
75
Neurocrine Biosciences
NBIX
$16.8B
$2.87M 0.34%
37,000
-50,000
-57% -$3.41M
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2017 Portfolio in Review

As of Q4 2017, Sphera Funds Management held 164 positions worth $852M, up 22% from $701M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sphera Funds Management deployed $154M of net new capital in Q4 2017, opening 33 new positions and adding to 26 existing holdings. Its largest new stake was Viatris: 756,449 shares worth $32M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 63% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Biogen, an estimated $9.88M trimmed.

  • Sphera Funds Management's largest Q4 2017 buy was Viatris: 756,449 shares worth $32M.
  • Sphera Funds Management added most to Vertex Pharmaceuticals in Q4 2017, an estimated $9.62M increase.
  • Sphera Funds Management's biggest Q4 2017 reduction was Biogen, cutting an estimated $9.88M.
  • Sphera Funds Management fully exited Gilead Sciences in Q4 2017, selling an estimated $18.6M.
  • Sphera Funds Management's ten largest holdings make up 47% of its $852M portfolio in Q4 2017.
  • Sphera Funds Management opened 33 new positions and closed 28 in Q4 2017.
  • Sphera Funds Management's portfolio value rose 22% quarter-over-quarter to $852M.

Based on Sphera Funds Management's 13F filing for Q4 2017, filed 12 Feb 2018.